Cargando…

Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab

INTRODUCTION: There is broad consensus that high-grade basal proteinuria and failure to achieve remission of proteinuria are key determinants of adverse renal prognosis in patients with primary membranous nephropathy. Since current regimens are not ideal due to short- and long-term toxicity and prop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waldman, Meryl, Beck, Laurence H., Braun, Michelle, Wilkins, Kenneth, Balow, James E., Austin, Howard A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138549/ https://www.ncbi.nlm.nih.gov/pubmed/27942609 http://dx.doi.org/10.1016/j.ekir.2016.05.002

Ejemplares similares

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

The predictive and prognostic value of peripheral blood antigen-specific memory B cells in phospholipase A2 receptor-associated membranous nephropathy
por: Zhu, Richard, et al.
Publicado: (2023)

Structural determinants of the dominant conformational epitopes of phospholipase A2 receptor in primary membranous nephropathy
por: Tang, Hong, et al.
Publicado: (2022)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
por: Liu, Yanan, et al.
Publicado: (2023)

Stepwise Treatment Using Corticosteroids Alone and in Combination with Cyclosporine in Korean Patients with Idiopathic Membranous Nephropathy
por: Shin, Dong Ho, et al.
Publicado: (2013)

Efficacy and safety of different dosing regimens of rituximab in primary membranous nephropathy: protocol for a systematic review and meta-analysis
por: Xu, Yongxing, et al.
Publicado: (2023)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
por: Lin, Shujun, et al.
Publicado: (2019)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
por: Gao, Shuang, et al.
Publicado: (2021)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

Significance of combined cyclosporine−prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial
por: Saito, Takao, et al.
Publicado: (2013)

Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial
por: Scolari, Francesco, et al.
Publicado: (2019)

Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety
por: Yu, Xiaojuan, et al.
Publicado: (2017)

Cyclosporine A-Induced Conchal Hyperplasia with Nasal Obstruction in a Patient with Membranous Nephropathy
por: Tillmann, Frank-Peter, et al.
Publicado: (2022)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report
por: Lu, Hui, et al.
Publicado: (2019)

Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study
por: Chen, Xian, et al.
Publicado: (2023)

COVİD-19 infection in a membranous nephropathy patient treated with rituximab
por: Elcioglu, Omer Celal, et al.
Publicado: (2020)

Treatment of membranous nephropathy with crescent nephritis by rituximab: A case report
por: Zhang, Fan, et al.
Publicado: (2022)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy
por: Bandak, Ghassan, et al.
Publicado: (2014)

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
por: Wang, Xiao-Pei, et al.
Publicado: (2016)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Rituximab Treatment in a Patient with Kimura Disease and Membranous Nephropathy: Case Report
por: Vissing-Uhre, Roald, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Established and Newly Proposed Mechanisms of Chronic Cyclosporine Nephropathy
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab
por: Akagi, Yuina, et al.
Publicado: (2021)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis
por: Lu, WanJun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qv365le0fphuj5bv3oes2e59kq